Sökning: onr:"swepub:oai:DiVA.org:liu-73363" >
A Randomized, Cross...
A Randomized, Cross-Over Study in Patients with Neuroendocrine Tumors (NETs) to Assess Patient Preference of Lanreotide Autogel Given by either Self/Partner or Healthcare Professional in NEUROENDOCRINOLOGY, vol 94, issue , pp 29-29
-
- Johanson, V (författare)
- Sahlgrens University Hospital
-
- Wilson, B. (författare)
- Odense University Hospital
-
- Abrahamsson, A. (författare)
- Karolinska University Hospital
-
visa fler...
-
- Jianu, C. (författare)
- St Olav Hospital
-
- Calissendorff, J. (författare)
- Karolinska University Hospital
-
- Wall, Najme (författare)
- Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US
-
- Gronbaek, H. (författare)
- Aarhus University Hospital
-
- Florholmen, J. (författare)
- Department Gastroenterol and Nutr, Tromso
-
- Granberg, D. (författare)
- University Hospital, Uppsala
-
- Ohberg, A. (författare)
- Ipsen AB
-
visa färre...
-
(creator_code:org_t)
- Karger, 2011
- 2011
- Engelska.
-
Ingår i: NEUROENDOCRINOLOGY. - : Karger. ; , s. 703-710
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.2...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Lanreotide Autogel® is supplied in prefilled syringes. Therefore, it is possible for patients with neuroendocrine tumors to use self-/partner-administered injections. The primary objective of this study was to assess the proportion of patients preferring self/partner injections over injections administered by health care professionals, and to describe the impact of self/partner administration on efficacy, safety, and costs. Methods: Of 62 eligible patients, 26 (42%) patients with neuroendocrine tumors treated with a stable dose of lanreotide Autogel 90 mg or 120 mg every 4 weeks agreed to participate in this Phase IV, international, open-label, crossover study, conducted at hospitals in Sweden, Norway, and Denmark. Patients were randomized to two blocks, starting with administration of lanreotide Autogel by either self/partner or a health care professional. Preference for injections administered by self/partner or health care professionals was measured, as well as efficacy, safety, and health care resource utilization (both direct and indirect costs). Results: Of 25 evaluable patients, 22 (88%) preferred self/partner injections, mainly because they experienced increased independence. Based on all patients asked to participate (n = 62), 35% preferred self/partner injections on a regular basis. There was no difference in efficacy or safety between the two administration blocks. Conclusion: Many patients with neuroendocrine tumors prefer self/partner injection of lanreotide Autogel, and are able to self/partner inject without any impact on efficacy or safety. This administration method seems to provide a good alternative for suitable patients to increase patient independence and reduce the number of clinic visits.
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- kon (ämneskategori)
- Av författaren/redakt...
-
Johanson, V
-
Wilson, B.
-
Abrahamsson, A.
-
Jianu, C.
-
Calissendorff, J ...
-
Wall, Najme
-
visa fler...
-
Gronbaek, H.
-
Florholmen, J.
-
Granberg, D.
-
Ohberg, A.
-
visa färre...
- Artiklar i publikationen
- NEUROENDOCRINOLO ...
- Av lärosätet
-
Linköpings universitet